0001171843-18-002469.txt : 20180402 0001171843-18-002469.hdr.sgml : 20180402 20180402170607 ACCESSION NUMBER: 0001171843-18-002469 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180402 DATE AS OF CHANGE: 20180402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC CENTRAL INDEX KEY: 0001105533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562110007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-215480 FILM NUMBER: 18729967 BUSINESS ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 BUSINESS PHONE: 9192876300 MAIL ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 FORMER COMPANY: FORMER CONFORMED NAME: MERIX BIOSCIENCE INC DATE OF NAME CHANGE: 20000207 424B5 1 f424b5_040218.htm 424B5

PROSPECTUS SUPPLEMENT

(To Prospectus dated January 24, 2017)

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-215480

ARGOS THERAPEUTICS, INC.

Up to $6,264,826

Common Stock

This prospectus supplement amends and supplements the information in the prospectus, dated January 24, 2017, filed as a part of our registration statement on Form S-3 (File No. 333-2215480), as previously supplemented by our prospectus supplement dated February 2, 2018, or the Prior Prospectus. On February 2, 2018, we amended and restated the original sales agreement dated May 8, 2015 to which we were a party with Cowen and Company, LLC, or Cowen, to increase the maximum aggregate offering price of the shares of our common stock that we may issue and sell from time to time under the sales agreement from $30,000,000 to $45,000,000. The Prior Prospectus only related to the $15,000,000 of additional shares of common stock that we may issue and sell as a result of the increase in the maximum aggregate offering price under the amended and restated sales agreement, or the Sales Agreement. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

Through April 2, 2018, we have not sold any shares of our common stock in accordance with the Sales Agreement under the Prior Prospectus. We are filing this prospectus supplement to amend the Prior Prospectus because we are now subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part. After giving effect to these limitations and the current public float of our common stock, and after giving effect to the terms of the Sales Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $6,264,826 under the Sales Agreement. If our public float increases such that we may sell additional amounts under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Our common stock is listed on The Nasdaq Capital Market under the symbol “ARGS.” The aggregate market value of our common stock held by non-affiliates as of April 2, 2018 pursuant to General Instruction I.B.6 is $18,794,478, which was calculated based on 10,183,792 shares of our common stock outstanding held by non-affiliates and at a price of $2.15 per share, the closing price of our common stock on January 31, 2018. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

Investing in these securities involves risks. See “Risk Factors” on page S-4 of the Prior Prospectus and documents incorporated by reference into the Prior Prospectus and in our most recent annual report on Form 10-K and in our most recent quarterly reports on Form 10-Q, and any amendments thereto, which are incorporated by reference into the Prior Prospectus; and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prior Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

Cowen

The date of this prospectus supplement is April 2, 2018